BMY vs. TEM: Bristol-Myers Squibb vs. Tempus AI Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while TEM is classified in Life Sciences Tools & Services.

Bristol-Myers Squibb (BMY) carries decades of public-market history since June 1, 1972, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the BMY side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while Bristol-Myers Squibb (BMY) is defensive at 0.19 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bristol-Myers Squibb (BMY) reports 44.01%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Bristol-Myers Squibb (BMY) reports 18.47%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Bristol-Myers Squibb (BMY) reports 33.79%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Bristol-Myers Squibb (BMY) at -0.22% is closer to the peer norm — faster top-line expansion for TEM.

Neither Bristol-Myers Squibb (BMY) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Bristol-Myers Squibb (BMY) at 1.59 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMY.

Debt sits unusually high against shareholders’ equity for both Bristol-Myers Squibb (BMY) at 1.91 and Tempus AI (TEM) at 2.86 — each debt-to-equity ratio is above its industry benchmark range.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Tempus AI (TEM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Bristol-Myers Squibb (BMY) trades at 13.78 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

Bristol-Myers Squibb (BMY) at 5.43 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

Valuation Metrics